

The Yeast Revolution

QuatrefloraTM and the New Frontier of Vaginal Health




Breaking the Taboo: Vaginal Health as a Key Focus for Holistic Wellness

Interest in supplements targeting intimate wellness and fungal infections has surged significantly, as consumers increasingly seek solutions for persistent quality-of-life issues affecting vaginal health.


This emerging priority reflects the broader shift toward comprehensive wellness strategies and proactive care regimens to maintain long-term intimate well-being. ⁽¹⁾

Supplement & Ingestible Concerns By Increase




Vaginal Infections: A Recurring Challenge Throughout a Woman's Life Journey

Throughout their lives, women experience several factors that may affect their intimate health. These factors can disrupt the normal ecological balance of the vaginal microbiota, leading to the overgrowth of pathogens. ⁽²⁻⁶⁾



QuatrefloraTM: The Yeast-Based Approach for Vaginal Health Concerns


QuatrefloraTM is an exclusive and patented probiotic yeast, registered as *S. cerevisiae* CNCM I-3856, with demonstrated clinically proven efficacy on vaginal health. ⁽⁷⁻⁸⁾



Unveiling the Science: How S. cerevisiae CNCM I-3856 Supports Vaginal Health

The probiotic *S. cerevisiae* CNCM I-3856 has been studied for over 20 years. Research on this strain has begun to reveal mechanisms of action underlying its beneficial effects on vaginal health. ⁽⁸⁻¹²⁾

Representation of the actions of S. cerevisiae CNCM I-3856 on the vagina



Why Choose Probiotic Yeast for Intimate Health?

QuatrefloraTM has been shown to migrate from intestinal flora to vaginal flora, where it may exert its beneficial effects.



References:

1. 2026 BEAUTY & WELLNESS PREDICTIONS: SPATE: Google, TikTok, Instagram US - from Dec 2024 to Nov 2025 vs. Dec 2023 to Nov 2024
2. Abou Chacra L, Fenollar F, Diop K. Bacterial vaginosis: what do we currently know? Frontiers in cellular and infection microbiology 11 (2022): 672429.
3. Willems HME, et al. Vulvovaginal candidiasis: a current understanding and burning questions. Journal of Fungi 6.1 (2020): 27.
4. Peebles K, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sexually Transmitted Diseases 46.5 (2019): 304-311.
5. Sobel, Jack D. "Vulvovaginal candidosis." The Lancet 369.9577 (2007): 1961-1971.
6. Denning DW, et al. Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet infectious diseases 18.11 (2018): e339-e347
7. Cayzele-Decherf A, Pélerin F, Justen P. Saccharomyces cerevisiae CNCM I-3856 as a natural breakthrough for vaginal health: A clinical study. Med. J. Obstet. Gynecol 5.4 (2017)
8. Sabbatini S, Monari C, Ballet N, Mosci P, Decherf AC, Pélerin F, Perito S, Scarpelli P, Vecchiarelli A. Saccharomyces cerevisiae-based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis. Virulence. 2018 Dec 31;9(1):954-966. doi: 10.1080/21505594.2018.1464362. PMID: 29683763; PMCID: PMC6037478.
9. Pericolini E, Gabrielli E, Ballet N, Sabbatini S, Roselletti E, Cayzele Decherf A, Pélerin F, Luciano E, Perito S, Justen P, Vecchiarelli A. Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis. Virulence. 2017 Jan 2;8(1):74-90. doi: 10.1080/21505594.2016.1213937. Epub 2016 Jul 19. PMID: 27435998; PMCID: PMC5963212.
10. Spacova I, Allonsius CN, De Boeck I, Oerlemans E, Tuytens I, Van de Vliet N, van den Broek MFL, Jimenez L, Boyer M, Rodriguez B, Ballet N, Lebeer S. Multifactorial inhibition of Candida albicans by combinations of lactobacilli and probiotic Saccharomyces cerevisiae CNCM I-3856. Sci Rep. 2024 Apr 23;14(1):9365. doi: 10.1038/s41598-024-59869-9. PMID: 38654026; PMCID: PMC11039719.
11. Gabrielli et al., 2018.
12. Sabbatini S, Monari C, Ballet N, Decherf AC, Bozza S, Camillon B, Perito S, Vecchiarelli A. Anti-Biofilm Properties of Saccharomyces cerevisiae CNCM I-3856 and Lactocaseibacillus rhamnosus ATCC 53103 Probiotics against G. vaginalis. Microorganisms. 2020 Aug 24;8(9):1294. doi:10.3390/microorganisms8091294. PMID: 32847138; PMCID: PMC7564297.
13. Blanquet-Diot S, Denis S, Chalancon S, Chaira F, Cardot JM, Alric M. Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans. Pharm Res. 2012 Jun;29(6):1444-53. doi: 10.1007/s11095-011-0620-5. Epub 2011 Nov 9. PMID: 22068280.
14. Decherf A, et al. Recovery of Saccharomyces cerevisiae CNCM I-3856 in vaginal samples of healthy women after oral administration. Nutrients 12, 8 (2020)